Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive condition that can be caused by genetic mutations or aging, and is characterized by accumulating heart damage that ultimately leads to symptoms of heart failure. In ATTR-CM,…
The most common signs of transthyretin amyloid cardiomyopathy (ATTR-CM) are those typically associated with heart failure, although problems in the nervous system or other tissues can also occur. ATTR-CM is a type of cardiac amyloidosis,…
A diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) is typically reached through a series of tests to identify signs of the disease and rule out related disorders. ATTR-CM is a type of heart amyloidosis, a group…
The treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) is a multidisciplinary effort involving interventions to slow disease progression and manage symptoms. ATTR-CM is a form of amyloidosis, where protein clumps, called amyloid deposits, accumulate in tissues.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a form of heart disease that’s typically caused by genetic mutations or aging. Determining the root cause of ATTR-CM can help guide treatment decisions, understand prognosis, and determine if family…
Latest News & Community Perspectives
Discussion
The oral therapy acoramidis has been approved in Brazil, to be sold as Beyonttra, for treating adults with hereditary or wild-type transthyretin amyloid cardiomyopathy (ATTR-CM). The regulatory clearance from the Agência Nacional de Vigilância…
Discussion
The U.S. Food and Drug Administration (FDA) has granted fast track designation to coramitug, an experimental treatment in late-stage clinical testing for transthyretin amyloid cardiomyopathy (ATTR-CM). The FDA gives this designation to investigational…
Discussion
A blood test measuring levels of the protein MR-proADM may help predict heart failure events (worsening of symptoms requiring immediate medical care) and death in people with transthyretin amyloid cardiomyopathy (ATTR-CM), a study showed.
Discussion
Starting Attruby (acoramidis) early and taking it continuously helps adults with transthyretin amyloid cardiomyopathy (ATTR-CM) live longer, stay out of the hospital for cardiovascular problems, and keep their heart function more stable over…
Discussion
People with wild-type transthyretin amyloid cardiomyopathy (ATTR-CM) are significantly more likely to have a history of agricultural work, manual labor, and greater upper-body physical strain than the general population, according to a registry-based study…
Discussion
Amvuttra (vutrisiran) was associated with improvements in quality of life and physical function in adults with transthyretin amyloidosis with cardiomyopathy (ATTR-CM). That’s according to new data from HELIOS-B (NCT04153149), the Phase 3…
Discussion
Alnylam Pharmaceuticals is supporting two initiatives aiming to transform transthyretin amyloid cardiomyopathy (ATTR-CM) management, with a focus on earlier diagnosis and more coordinated care. The initiatives involve artificial intelligence (AI) tools and multidisciplinary…
Discussion
Women with transthyretin amyloid cardiomyopathy (ATTR-CM) show differences in disease features and greater physical limitations than men, but are less likely to be given certain treatments, according to a study in Spain. In addition,…
Discussion
Blood levels of the transthyretin (TTR) protein at the start of Vyndaqel (tafamidis) treatment and after one month may help identify which patients with wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) are responding well and…
Discussion
The U.S. Food and Drug Administration (FDA) has lifted its hold on a large-scale clinical trial evaluating nexiguran ziclumeran, Intellia Therapeutics’ gene-editing therapy candidate, known as nex-z for short, in adults with transthyretin…